Lexaria signs contracts for human study of oral semaglutide formulation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall St futures mixed as investors await payrolls data
- Oil falls for a third straight day after US, Iran conclude talks in Doha
- Dollar eases as yen gains ahead of US payrolls, chipmaker stocks struggle
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
Lexaria to Begin New Human Clinical Study in GLP-1
April 1, 2026 9:20 AM EDTContracts signed for Human Pilot Study #7 (GLP-1-H26-7)
KELOWNA, BC / ACCESS Newswire / April 1, 2026 / Lexaria Bioscience Corp. (NASDAQ: LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the engagement of the contract research organization ("CRO") to execute and report on its Human Pilot Study #7 (GLP-1-H26-7) that will evaluate 2 oral DehydraTECH-semaglutide ("DHT-sema") compositions against commercially available Wegovy® tablets (the "Study").
Contracts with the CRO have been signed... More
